vimarsana.com

Latest Breaking News On - Mcy 0141 for - Page 1 : vimarsana.com

EQS-News: Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis

EQS-News: Imcyse SA / Key word(s): Study Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis 13.09.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Imcyse Announces Complet.

Region flamandeDenis bedoretAndrew mackieAnne hennecke lydia robinson garciaJean van rampelberghChuck padalaMc servicesCatholic university of leuvenDistribution servicesData monitoring committeeAnnounces completionMultiple sclerosisVan rampelberghIndependent data monitoring committeeMyelin oligodendrocyte glycoproteinCatholic university

DGAP-News: Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis

DGAP-News: Imcyse SA / Key word(s): Study 13.04.2022 / 13:00 The issuer is solely responsible for the content of this announcement. Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis IMCY-MS-001 study aims to determine safe.

Walloon regionWaals gewestRegion flamandeDenis bedoretAnne hennecke julia bittnerPatrick vermerschJonathan nugentAndrew mackieMc servicesUniversity of lilleCatholic university of leuvenDistribution servicesAnnounces first patient dosedMyelin oligodendrocyte glycoproteinCatholic universityMedia inquiries

vimarsana © 2020. All Rights Reserved.